|
1
|
Katayama H, Brinkly WR and Sen S: The
Aurora kinases: role in cell transformation and tumorigenesis.
Cancer Metastasis Rev. 22:451–464. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Agnese V, Bazan V, Fiorentino FP, et al:
The role of Aurora-A inhibitors in cancer therapy. Ann Oncol.
6:vi47–vi52. 2007.PubMed/NCBI
|
|
3
|
Carmena M and Earnshaw WC: The cellular
geography of aurora kinases. Nat Rev Mol Cell Biol. 4:842–854.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Glover DM, Leibowitz MH, McLean DA and
Parry H: Mutations in aurora prevent centrosome separation leading
to the formation of monopolar spindles. Cell. 81:95–105. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chung CM, Man C, Jin Y, et al:
Amplification and overexpression of aurora kinase A (AURKA) in
immortalized human ovarian epithelial (HOSE) cells. Mol Carcinog.
43:165–174. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Anand S, Penrhyn-Lowe S and Venkitaraman
AR: AURORA-A amplification overrides the mitotic spindle assembly
checkpoint, inducing resistance to Taxol. Cancer cell. 3:51–62.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang D, Shimizu T, Araki N, et al: Aurora
A overexpression induces cellular senescence in mammary gland
hyperplastic tumors developed in p53-deficient mice. Oncogene.
27:4305–4314. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hsueh KW, Fu SL, Huang CY and Lin CH:
Aurora-A phosphorylates hnRNPK and disrupts its interaction with
p53. FEBS Lett. 585:2671–2675. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Santaguida S, Vernieri C, Villa F,
Ciliberto A and Musacchio A: Evidence that Aurora B is implicated
in spindle checkpoint signalling independently of error correction.
EMBO J. 30:1508–1519. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kimmins S, Crosio C, Kotaja N, et al:
Differential functions of the Aurora B and Aurora C kinases in
mammalian spermatogenesis. Mol Endocrinol. 21:726–739. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li M, Jung A, Ganswindt U, Marini P, et
al: Aurora kinase inhibitor ZM447439 induces apoptosis via
mitochondrial pathways. Biochem Pharmacol. 79:122–129. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hauf S, Cole RW, LaTerra S, et al: The
small molecule Hesperadin reveals a role for Aurora B in correcting
kinetochore-microtubule attachment and in maintaining the spindle
assembly checkpoint. J Cell Biol. 161:281–294. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Harrington EA, Bebbington D, Moore J, et
al: VX-680, a potent and selective small-molecule inhibitor of the
Aurora kinases, suppresses tumor growth in vivo. Nat Med.
10:262–267. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gora-Tybor J and Robak T: Targeted drugs
in chronic myeloid leukemia. Current Med Chem. 15:3036–3051. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Young MA, Shah NP, Chao LH, et al:
Structure of the kinase domain of an imatinib-resistant Abl mutant
in complex with the Aurora kinase inhibitor VX-680. Cancer Res.
66:1007–1014. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mancini M, Aluigi M, Leo E, et al: Histone
H3 covalent modifications driving response of
BCR-ABL1+cells sensitive and resistant to imatinib to
Aurora kinase inhibitor MK-0457. Br J Haematol. 156:265–268.
2012.PubMed/NCBI
|
|
17
|
Tyler RK, Shpiro N, Marquez R and Eyers
PA: VX-680 inhibits Aurora A and Aurora B kinase activity in human
cells. Cell Cycle. 6:2846–2854. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Traynor AM, Hewitt M, Liu G, et al: Phase
I dose escalation study of MK-0457, a novel Aurora kinase
inhibitor, in adult patients with advanced solid tumors. Cancer
Chemother Pharmacol. 67:305–314. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gontarewicz A, Balabanov S, Keller G, et
al: Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by
the small molecule inhibitor PHA-739358 is effective against
imatinib-resistant BCR-ABL mutations including T315I. Blood.
111:4355–4364. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arkenau HT, Plummer R, Molife LR, et al: A
phase I dose escalation study of AT9283, a small molecule inhibitor
of aurora kinases, in patients with advanced solid malignancies.
Ann Oncol. 23:1307–1313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schwartz GK, Carvajal RD, Midgley R, et
al: Phase I study of barasertib (AZD1152), a selective inhibitor of
Aurora B kinase, in patients with advanced solid tumors. Invest New
Drugs. Jun 2–2012.(E-pub ahead of print).
|
|
22
|
Aihara A, Tanaka S, Yasen M, et al: The
selective Aurora B kinase inhibitor AZD1152 as a novel treatment
for hepatocellular carcinoma. J Hepatol. 52:63–71. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Macarulla T, Cervantes A, Elez E, et al:
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in
patients with advanced solid tumors: safety, pharmacokinetics, and
pharmacodynamics. Mol Cancer Ther. 9:2844–2852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sehdev V, Peng D, Soutto M, et al: The
aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell
death in esophageal adenocarcinoma cells. Mol Cancer Ther.
11:763–774. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Venkataraman S, Alimova I, Tello T, et al:
Targeting Aurora Kinase A enhances radiation sensitivity of
atypical teratoid rhabdoid tumor cells. J Neurooncol. 107:517–526.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li P, Zhou Q, Ren L and Xiao L: Clinical
implication of the expression of Aurora B in normal endometrium and
endometrial carcinoma. J Huazhong Univ Sci Technolog Med Sci.
337–339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kurai M, Shiozawa T, Shih HC, et al:
Expression of Aurora kinases A and B in normal, hyperplastic, and
malignant human endometrium: Aurora B as a predictor for poor
prognosis in endometrial carcinoma. Hum Pathol. 36:1281–1288. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moreno-Bueno G, Sánchez-Estévez C, Cassia
R, et al: Differential gene expression profile in endometrioid and
nonendometrioid endometrial carcinoma: STK15 is frequently
overexpressed and amplified in nonendometrioid carcinomas. Cancer
Res. 63:5697–5702. 2003.
|
|
29
|
Yang F, Guo X, Yang G, Rosen DG and Liu J:
AURKA and BRCA2 expression highly correlate with prognosis of
endometrioid ovarian carcinoma. Mod Pathol. 24:836–845. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin YG, Immaneni A, Merritt WM, et al:
Targeting aurora kinase with MK-0457 inhibits ovarian cancer
growth. Clin Cancer Res. 14:5437–5446. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Beussel S, Hasenburg A, Bogatyreva L,
Hauschke D, Werner M and Lassmann S: Aurora-B protein expression is
linked to initial response to taxane-based first-line chemotherapy
in stage III ovarian carcinoma. J Clin Pathol. 65:29–35. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang L and Zhang S: ZM447439, the Aurora
kinase B inhibitor, suppresses the growth of cervical cancer SiHa
cells and enhances the chemosensitivity to cisplatin. J Obstet
Gynaecol Res. 37:591–600. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun C, Chan F, Briassouli P and
Linardopoulos S: Aurora kinase inhibition downregulates NF-kappaB
and sensitises tumour cells to chemotherapeutic agents. Biochem
Biophys Res Commun. 352:220–225. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tao Y, Zhang P, Girdler F, et al:
Enhancement of radiation response in p53-deficient cancer cells by
the Aurora-B kinase inhibitor AZD1152. Oncogene. 27:3244–3255.
2008. View Article : Google Scholar : PubMed/NCBI
|
